University of British Columbia, Canada

The University of British Columbia in Canada is a global academic institution. The inventor of the sy-007 project jointly developed by Suzhou Yabao and the University of British Columbia in Canada is a Canadian academician. Sy-007 is a new interference peptide targeting a new target (PTEN). It belongs to the global first in class drug, and the treatment indication is stroke. At present, sy-007 phase I a clinical study has been completed and phase I B multicenter clinical study is being started.

Next:Lilly pharmaceutical